Effect | None |
Trial Design | Double blind |
Trial Length | 1-6 months |
Number of Subjects | 37 |
Sex | Male |
Age Range | 45-64 |
Body Types | Overweight |
In men with a history of colon cancer given 80mg Promensil (40mg twice daily) over the course of eight weeks failed to significantly reduce IGF-1 (free or total) and IGF-II while all three binding proteins (IGFBP1-3) were also similarly not affected. In controlling for those who produced equol (23% of sample; those with serum equol higher than 83nM) there was a decrease in total IGF-1 whereas the binding proteins were still unaffected.